| 1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 3. |
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61.
|
| 4. |
Amjad W, Seo DJ. Is late detection of hepatocellular cancer associated with better clinical outcome[J]. Clin Gastroenterol Hepatol, 2022, 20(9): 2149-2150.
|
| 5. |
Li M, Lin S, Wilson L, et al. Cost-effectiveness analysis of hepatic arterial infusion of FOLFOX combined sorafenib for advanced hepatocellular carcinoma with portal vein invasion[J]. Front Oncol, 2021, 11: 562135.
|
| 6. |
Leung HW, Liu CF, Chan AL. Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma[J]. Radiat Oncol, 2016, 11: 69.
|
| 7. |
Zhao Q, He Y, Nian Z, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost-utility analysis in China and the United States[J]. Front Pharmacol, 2025, 16: 1404389.
|
| 8. |
Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects[J]. Curr Drug Metab, 2009, 10(5): 470-481.
|
| 9. |
Akk?n S, Varan G, Bilensoy E. A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers[J]. Molecules, 2021, 26(11): 3382.
|
| 10. |
Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular carcinoma: results of a randomized phase III trial[J]. J Clin Oncol, 2013, 31(32): 4067-4075.
|
| 11. |
Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873.
|
| 12. |
原發性肝癌診療指南(2024年版)[J]. 肝癌電子雜志, 2024, 11(2): 1-26.
|
| 13. |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
|
| 14. |
Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146.
|
| 15. |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
|
| 16. |
Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol, 2021, 39(27): 3002-3011.
|
| 17. |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
|
| 18. |
Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2023, 9(12): 1651-1659.
|
| 19. |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
|
| 20. |
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
|
| 21. |
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414): 557-560.
|
| 22. |
Su Y, Fu J, Du J, et al. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis[J]. Ther Adv Med Oncol, 2020, 12: 1758835920950199.
|
| 23. |
Williams C, Lewsey JD, Mackay DF, et al. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling[J]. Med Decis Making, 2017, 37(4): 427-439.
|
| 24. |
劉國恩. 中國藥物經濟學評價指南2020[M]. 北京: 中國市場出版社, 2020: 43-47.
|
| 25. |
Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves[J]. BMC Med Res Methodol, 2012, 12: 9.
|
| 26. |
閆文英, 楊娜, 張冉冉, 等. 安羅替尼聯合派安普利單抗一線治療不可切除肝細胞癌的成本-效用分析[J]. 中國藥房, 2026, 37(3): 344-349.
|
| 27. |
Meng R, Cao Y, Zhou T, et al. The cost effectiveness of donafenib compared with sorafenib for the first-line treatment of unresectable or metastatic hepatocellular carcinoma in China[J]. Front Public Health, 2022, 10: 794131.
|
| 28. |
Zhao M, Pan X, Yin Y, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis[J]. Front Public Health, 2022, 10: 869960.
|
| 29. |
Chiang CL, Chan SK, Lee SF, et al. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis[J]. Cancers (Basel), 2021, 13(5): 931.
|
| 30. |
Shu Y, Tang Y, Ding Y, et al. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma[J]. Int Immunopharmacol, 2023, 122: 110543.
|
| 31. |
Zhou T, Cao Y, Wang X, et al. Economic evaluation of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma[J]. Adv Ther, 2022, 39(5): 2165-2177.
|
| 32. |
Xiang G, Huang Y, Zhang N, et al. First-line camrelizumab plus rivoceranib in advanced hepatocellular carcinoma: a China-based cost-effectiveness analysis[J]. Clin Med Insights Oncol, 2024, 18: 11795549241299393.
|
| 33. |
Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6[J]. Med Decis Making, 2012, 32(5): 722-732.
|
| 34. |
Sun Y, Xu K, Yao H, et al. Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe[J]. Int J Clin Pharm, 2025, 47(1): 196-209.
|
| 35. |
Wen F, Zheng H, Zhang P, et al. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis in China and the United States[J]. Liver Int, 2021, 41(5): 1097-1104.
|
| 36. |
Guan H, Wang C, Zhao Z, et al. Cost-effectiveness of donafenib as first-line treatment of unresectable hepatocellular carcinoma in China[J]. Adv Ther, 2022, 39(7): 3334-3346.
|
| 37. |
Li L, Yang S, Chen Y, et al. Immune checkpoint inhibitors plus an anti-VEGF antibody as the first-line treatment for unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis[J]. Front Pharmacol, 2022, 13: 891008.
|